Glenmark Strengthens Diabetes Franchise with India Launch of Empagliflozin

Unknown Apr 02, 2026 700 Views

Glenmark Pharmaceuticals Limited announced the commercial availability of Empagliflozin, a globally established SGLT2 inhibitor, in India on 12th March, 2025. The medication will be promoted under the trademark Glempa (Empagliflozin 10/25 mg) and fixed-dose combinations Glempa-L (Empagliflozin +...

Stay Ahead – Explore Now! Germany Merz Cites US Military Might as Blueprint for Ukraine Peace